In Europe there are currently two biosimilars registered, and we completed recently two confirmative trials on follicular lymphomas and in both trials, the results were absolutely super imposable for rituximab. These results suggest the registration of those particles is not going to improve efficacy, but it will bring us this efficacy at a more affordable price. Wojciech Jurczak, from the Jagiellonian University, Krakow, Poland, mentions how this price reduction with biosimilars is absolutely necessary if we want to introduce all the new drugs and new technologies into the treatment landscape. Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.